José Barrueco

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, R. Kaiser, Anders Mellemgaard et al. · The Lancet Oncology · 2014 · 931 citations · Full text

Oncology, Nintedanib Versus Docetaxel, Lume-lung 1 +10

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

Charles S. Fuchs, John L. Marshall, Edith P. Mitchell et al. · Journal of Clinical Oncology · 2007 · 854 citations

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Giorgio V. Scagliotti, Rabab Gaafar, Anna K. Nowak et al. · The Lancet Respiratory Medicine · 2019 · 164 citations

Placebo-controlled Phase 3, Pleural Disease, Anti-cancer Agent +6

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Federica Grosso, Nicola Steele, Silvia Novello et al. · Journal of Clinical Oncology · 2017 · 138 citations · Full text

Cancer Management, Pathology, Metronomic Chemotherapy +16

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Lung Cancer · 2016 · 86 citations

Medicine, Pharmacology, Clinical Trials +8